32 / 40
Evidencia en pacientes pretratados
Amado RG, et al. J Clin Oncol 2008; 26:1626-34
.
Parametre
Panitumumab
(n=499)
Cetuximab
(n=500)
OS − median, months
10.4
10.0
HR (95% CI)
0.97 (0.84−1.11)
Z-score (P-value)
−3.19 (P=0.0007)
Retention rate, % (95% CI)
105.7 (81.9−129.5)
PFS − median, months
4.1
4.4
HR (95% CI)
1.00 (0.88−1.14)
Patients with measurable
disease
(n=486)
(n=485)
ORR, n (%)
107 (22.0)
96 (19.8)
Odds ratio (95% CI)
1.15 (0.83−1.58)
Price TJ, et al. Lancet Oncol 2014;15:569−79
mCRC
WT
KRAS
exon 2
(n=999)